EFFECT OF CHRONIC EXPOSURE TO LEAD ON GABA BINDING IN DEVELOPING RAT-BRAIN

被引:6
作者
DREW, CA
SPENCE, I
JOHNSTON, GAR
机构
[1] Department of Pharmacology, The University of Sydney
关键词
D O I
10.1016/0197-0186(90)90066-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The effect of chronic treatment with lead on the growth and the development of calcium-dependent GABAB (forebrain and cerebellum) and calcium-independent GABAA binding (forebrain), at 10, 21 and 84 days post-natally (PN), was studied in rats whose dams received either lead acetate (7 gl-1, 18.5 mM) or sodium acetate (controls) in their drinking water from conception to weaning and normal animals given only water. The body and brain weight of lead treated pups was significantly less than that of normal and control pups. Chronic lead treatment produced receptor specific effects on binding at different times during development. In the forebrain GABAA binding was reduced at PN 10 (decreased affinity and density) but showed increased receptor density at PN 84. GABAB binding, while reduced during the developmental period (increased affinity and decreased density), appeared to have recovered at maturity. The development of cerebellar calcium-dependent binding was more variable in showing an increase in affinity in adult animals and decreased density at PN 10 and 84. There was no difference in normal and control binding except at PN 10 for both GABAA and GABAB binding. Chronic lead treatment affects calcium-dependent and calcium-independent binding differently suggesting that within the period of greatest vulnerability to the effects of lead, development in different receptor systems may be affected in quite different ways according to the role of calcium in their normal function. © 1990.
引用
收藏
页码:43 / 51
页数:9
相关论文
共 48 条
[1]  
[Anonymous], 1979, CONCEPT BLOOD BRAIN
[2]  
AVERILL DR, 1980, LOW LEVEL LEAD EXPOS, P201
[3]  
BOWERY N G, 1985, British Journal of Pharmacology, V85, p234P
[4]  
BOWERY NG, 1983, GABA RECEPTORS, P177
[5]  
BOWERY NG, 1983, BRIT J PHARMACOL, V79, pP189
[6]  
BOWERY NG, 1983, BRIT J PHARMACOL, V79, pP277
[7]  
BULL RJ, 1983, NEUROTOXICOLOGY, V4, P1
[8]  
CROSSMAN AR, 1983, BRIT J PHARMACOL, V80, pP532
[9]  
DER R, 1977, RES COMMUN CHEM PATH, V17, P237
[10]  
Dobbing J., 1968, APPLIED NEUROCHEMIST, P287